Recently, a phase II clinical trial evaluating the efficacy and safety of neoadjuvant osimertinib (80 mg QD for 6 weeks) for resectable EGFR-mutated lung adenocarcinoma (NEOS study) updated its findings at the 2022 ELCC meeting. The gene discussed is EGFR; the disease is lung adenocarcinoma.